Core Viewpoint - Shenzhen Hanno Medical Technology Co., Ltd. is the first domestic company to successfully develop and obtain approval for the ECMO (Extracorporeal Membrane Oxygenation) system, aiming for an IPO on the Sci-Tech Innovation Board by the end of 2025, despite currently not being profitable and facing significant financial challenges [1][3][9]. Financial Performance - Hanno Medical has reported continuous losses over the past three and a half years, with cumulative losses exceeding 600 million yuan, and net profits for 2022, 2023, and the first half of 2025 being -64.79 million yuan, -341 million yuan, and -82.27 million yuan respectively [3][7]. - The company's revenue from its core product, Lifemotion ECMO system, has been limited, with reported revenues of approximately 0 yuan, 29.83 million yuan, 49.31 million yuan, and 37.35 million yuan for the respective years [7]. - The cash flow from operating activities has consistently been negative, with figures of -84.01 million yuan, -35.19 million yuan, -119 million yuan, and -71.57 million yuan during the same periods [9]. Market Potential - The ECMO market in China is projected to grow significantly, reaching 3.71 billion yuan by 2030, with a compound annual growth rate (CAGR) of 25.2% from 2024 to 2030, and 10.73 billion yuan by 2035, with a CAGR of 23.7% from 2030 to 2035 [6]. - The demand for ECMO treatment is increasing, with a notable gap in device availability per capita compared to developed countries, indicating substantial market potential for domestic products [6]. Challenges and Barriers - Hanno Medical faces several barriers to commercializing its ECMO system, including high technical and cost barriers, market monopolization by imported brands, inadequate clinical training and support systems, and a lengthy profitability cycle due to high initial R&D and market entry costs [8]. - The company's asset-liability ratio has been rising, reaching 72.36% by the latest reporting period, significantly higher than the industry average, which raises concerns about financial stability and the ability to cover interest expenses [9][10]. IPO and Future Plans - Following the acceptance of its IPO application on December 23, 2025, Hanno Medical was selected for a site inspection as part of the regulatory process, which aims to enhance the quality of listed companies and prevent financial fraud [4][5]. - The company plans to raise 1.062 billion yuan through its IPO, which will be allocated to R&D center construction, production base development, marketing network establishment, and working capital supplementation [11].

Core Viewpoint - Shenzhen Hanno Medical Technology Co., Ltd. is the first domestic company to successfully develop and obtain approval for the ECMO system, aiming for an IPO on the Sci-Tech Innovation Board by the end of 2025 [1][3]. Financial Performance - Hanno Medical has reported significant losses over the past three and a half years, totaling over 600 million yuan, with net profits of -64.79 million yuan in 2022, -341 million yuan in 2023, -183 million yuan in 2024, and -82.27 million yuan in the first half of 2025 [3][7]. - The company has consistently negative cash flow from operating activities, with figures of -84.01 million yuan, -35.19 million yuan, -119 million yuan, and -71.57 million yuan during the reporting periods [9]. - The asset-liability ratio has been increasing, reaching 72.36% in the first half of 2025, significantly higher than the industry average [9][10]. Market Potential - The ECMO market in China is expected to grow significantly, projected to reach 3.71 billion yuan by 2030, with a compound annual growth rate (CAGR) of 25.2% from 2024 to 2030 [6]. - The demand for ECMO treatment is increasing, with the number of cases rising annually, while the per capita equipment availability is still low compared to developed countries, indicating a substantial market gap [6]. Product Development and Challenges - Hanno Medical's core product, the Lifemotion ECMO system, has generated limited revenue since its launch, failing to cover substantial R&D investments [7]. - The company faces several barriers to commercializing its ECMO products, including high technical and cost barriers, market monopolization by imported brands, inadequate training and support systems, and long-term profitability challenges [8]. IPO and Future Plans - Hanno Medical's IPO application was accepted on December 23, 2025, and it is the only pharmaceutical company selected for on-site inspection in the first batch of 2026 [3][4]. - The company plans to raise 1.062 billion yuan through the IPO, which will be allocated to R&D center construction, production base development, marketing network establishment, and working capital supplementation [10].

Core Viewpoint - Shenzhen Hanno Medical Technology Co., Ltd. is the first domestic company to successfully develop and obtain approval for the ECMO system, aiming for an IPO on the Sci-Tech Innovation Board by the end of 2025, despite currently not being profitable and facing significant financial challenges [1][4]. Financial Performance - The total assets of Hanno Medical as of June 30, 2025, are approximately 496.07 million yuan, with a continuous increase in asset-liability ratio, reaching 72.36% [2][10]. - The company reported net profits of -64.79 million yuan in 2022, -341 million yuan in 2023, -182.79 million yuan in 2024, and -82.27 million yuan in the first half of 2025, accumulating losses exceeding 600 million yuan over three and a half years [4][8]. - Operating revenues for the same periods were approximately 0 yuan in 2022, 29.83 million yuan in 2023, 49.31 million yuan in 2024, and 37.35 million yuan in the first half of 2025 [8]. Market Potential - The ECMO market in China is expected to grow significantly, projected to reach 3.71 billion yuan by 2030, with a compound annual growth rate (CAGR) of 25.2% from 2024 to 2030, and 10.73 billion yuan by 2035, with a CAGR of 23.7% from 2030 to 2035 [6]. Challenges in Commercialization - Hanno Medical faces several barriers to the commercialization of its ECMO system, including high technical and cost barriers, market monopolization by imported brands, inadequate clinical training and support systems, and a lengthy profitability cycle due to substantial upfront R&D and market investment [8][9]. IPO and Regulatory Scrutiny - Hanno Medical's IPO application was accepted on December 23, 2025, and the company was selected for on-site inspection as part of the first batch of enterprises for 2026, highlighting the importance of regulatory oversight in ensuring the quality of listed companies [5][11].

Core Viewpoint - Shenzhen Hanno Medical Technology Co., Ltd. has submitted its IPO application to the Shanghai Stock Exchange for listing on the Sci-Tech Innovation Board, aiming to leverage the fifth set of listing standards, marking it as the first domestic company to have its ECMO system approved for market entry [1][2]. Financial Performance - Hanno Medical is experiencing rapid growth, with revenue projected to increase from 29.83 million yuan in 2023 to 49.31 million yuan in 2024, and 37.36 million yuan achieved in the first half of 2025. The company's losses have significantly narrowed from 341 million yuan in 2023 to 82.27 million yuan in the first half of 2025, indicating improved operational efficiency [2]. Fundraising and Investment - The company plans to raise 1.06 billion yuan through its public offering, which will be allocated to R&D centers, production bases, marketing network construction, and working capital, aligning with its long-term strategy and national policies promoting high-end medical equipment development [3]. Technological Innovation - Hanno Medical emphasizes independent innovation, having developed all key technologies in-house, maintaining a leading edge in the industry. The company has mastered seven core technologies and holds 38 authorized invention patents, establishing a strong competitive barrier [4]. Product Development - The core product, Lifemotion ECMO system, was approved for market entry in 2023, breaking foreign monopolies. It received EU CE MDR certification in early 2025, becoming the first domestic ECMO product to enter international markets [4]. Market Coverage - The company's products have been adopted by over 140 hospitals nationwide, including top-tier hospitals, and have achieved international orders in Europe, South America, and Africa, with ongoing product registration efforts in emerging markets [6][7]. Market Growth Potential - The ECMO industry is projected to grow significantly, with the Chinese market expected to expand from 960 million yuan in 2024 to 3.71 billion yuan by 2030, reflecting a compound annual growth rate of 25.2%. The global market is anticipated to reach 5.8 billion USD by 2035 [7]. Business Model - Hanno Medical has established a sustainable business model centered on "equipment first, consumables driven," ensuring predictable cash flow through the continuous consumption of high-value consumables associated with ECMO systems. This model is expected to replicate in broader international markets, contributing to long-term value [8].

Core Viewpoint - Shenzhen Hanno Medical Technology Co., Ltd. has submitted its IPO application to the Shanghai Stock Exchange for listing on the Sci-Tech Innovation Board, marking a significant milestone as the first domestic company to achieve market approval for ECMO systems, indicating a key leap in China's high-end life support equipment sector [1] Financial Performance - Hanno Medical is experiencing rapid growth, with revenue projected to increase from 29.83 million yuan in 2023 to 49.31 million yuan in 2024, and 37.36 million yuan in the first half of 2025; losses are expected to narrow significantly from 341 million yuan in 2023 to 82.27 million yuan in the first half of 2025 [2] - The company has completed 10 rounds of financing since its establishment, attracting investments from notable institutions, reflecting strong market recognition of its technological capabilities and growth prospects [2] - The company plans to raise 1.06 billion yuan through its public offering, which will be allocated to R&D, production, marketing network development, and working capital, aligning with its long-term strategy and national policies promoting domestic high-end medical equipment [2] Technological Innovation - Hanno Medical emphasizes independent innovation, having developed all key technologies in-house, maintaining a significant competitive edge in the industry; it has mastered seven core technologies and holds 38 authorized patents, establishing a robust technological foundation for future product development [3][4] Market Position and Product Development - The company's core product, the Lifemotion ECMO system, received market approval in 2023, breaking the long-standing technological monopoly held by countries like the US, Germany, and Italy; it also obtained EU CE MDR certification in early 2025, marking it as the first domestic ECMO product to enter the international market [4][6] - Hanno Medical's product offerings span a comprehensive range of life support solutions, including ECMO, ECPR, CPS, and Low-Flow systems, demonstrating clear clinical value and sustainable commercial growth potential [5] International Expansion - As of June 30, 2025, the Lifemotion ECMO system has been adopted by over 140 hospitals in China, including top-tier institutions, and has successfully entered international markets in Europe, South America, and Africa, with ongoing product registration efforts in various countries [6][7] - The CE certification signifies that Hanno Medical's products meet international standards for quality, safety, and effectiveness, enhancing global market trust and enabling participation in international competition [7] Industry Growth Potential - The ECMO industry is projected to grow significantly, with the Chinese market expected to expand from 960 million yuan in 2024 to 3.71 billion yuan by 2030, reflecting a compound annual growth rate of 25.2%; the global market is anticipated to reach 5.8 billion USD by 2035 [8] - Hanno Medical has established a sustainable business model centered on "equipment first, consumables driven," ensuring predictable cash flow and market penetration, with plans to replicate this model in international markets [9]